What are the most important amylin agonists used in clinical practice?

Most Important Amylin Agonists in Clinical Practice

Pramlintide is currently the only FDA-approved amylin agonist available for clinical use, indicated as adjunctive therapy with mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved adequate glycemic control. 1, 2, 3, 4, 1, 5

Currently Available Agent

Pramlintide (Approved)

• Mechanism: Synthetic analog of the naturally occurring β-cell peptide amylin 1, 2
• Administration: Subcutaneous injection before meals 2
• Efficacy:
  • A1C reduction of 0.3-0.4% 1, 5
  • Weight loss of 1-2 kg over 6 months 2, 4, 1
• Key actions:
  • Slows gastric emptying
  • Suppresses postprandial glucagon secretion
  • Reduces postprandial glucose excursions 2
  • Promotes satiety 6
• Critical requirement: When initiating pramlintide, prandial insulin doses must be reduced to minimize severe hypoglycemia risk 6
• Limitations:
  • Gastrointestinal side effects (nausea) in ~30% of patients, though this typically abates over time 2
  • Only approved for use with insulin therapy 2

Emerging Agents in Development

While not yet approved, several next-generation amylin-based therapies are advancing through clinical trials and represent the future of this drug class 7, 8, 9:

Long-Acting Amylin Analogs

• Cagrilintide: Dual amylin/calcitonin receptor agonist with once-weekly dosing 7, 8
• Eloralintide, Petrelintide, MET-233, AZD6234: Various long-acting formulations showing enhanced efficacy in trials 7, 8

Combination Therapy

• CagriSema: Co-formulation of cagrilintide with semaglutide (GLP-1 receptor agonist), demonstrating superior weight loss and glycemic control compared to either agent alone 7, 10

Clinical Context and Positioning

Pramlintide should be considered when:

• Patients with type 1 or type 2 diabetes on insulin therapy have not achieved glycemic targets
• Postprandial glucose control is inadequate despite optimized insulin regimens
• Weight management is a concurrent concern with diabetes control 11

Important caveats:

• The modest A1C reduction (0.3-0.4%) means pramlintide is not a first-line agent but rather an adjunct to optimize insulin therapy 1, 5
• Gastrointestinal tolerability requires gradual dose titration 2
• Unlike GLP-1 receptor agonists, pramlintide does not stimulate insulin secretion—it works through complementary mechanisms 2
• The requirement for co-administration with insulin limits its use compared to newer incretin-based therapies 2

The amylin agonist class remains relatively limited in clinical practice, with pramlintide being the sole representative, though the pipeline of long-acting analogs suggests this therapeutic category will expand significantly in coming years 7, 8, 9.